SCHEDULE: Citadel Discloses 9.6% Stake in Lexeo Therapeutics
Beneficial Ownership Disclosure
Citadel and its affiliates, including Kenneth Griffin, have disclosed a 9.6% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 5,325,269 shares of Lexeo Therapeutics, Inc. common stock, representing 9.6% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 8,843 shares, representing 0.0% of the common stock.
- Kenneth Griffin beneficially owns 5,334,112 shares, representing 9.6% of the common stock.
- The beneficial ownership percentages are calculated based on 55,718,516 shares outstanding, which includes 54,001,214 shares outstanding as of June 2, 2025, and 1,717,302 shares issuable upon conversion of certain warrants held by affiliates of the reporting persons.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant institutional ownership stake. While not directly indicative of company performance, a large investment by a prominent firm like Citadel can be viewed as a neutral to slightly positive signal of interest in the company's equity.
Positives
- A significant institutional investment from Citadel, a prominent financial firm, indicates a notable position in Lexeo Therapeutics' equity.
Negatives
- No specific negative information is disclosed in this ownership filing.
Risks
- This filing is an ownership disclosure and does not detail specific risks related to Lexeo Therapeutics' operations or financial health.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by a major hedge fund and market maker, Citadel, in Lexeo Therapeutics. Such filings are routine disclosures required when an entity acquires more than 5% of a company's voting shares, signaling institutional interest in the company's equity.
Comparison to Industry Standards
- This filing is a standard disclosure of beneficial ownership, common for large institutional investors like Citadel. It does not provide performance metrics for direct comparison to industry standards.
Stakeholder Impact
- Shareholders: May view the significant institutional investment by Citadel as a positive signal of confidence or interest in Lexeo Therapeutics' stock.
Key Dates
| Date | Description |
|---|---|
| 2025-06-02 | Date of shares outstanding calculation (54,001,214 shares) according to the issuer's registration statement. |
| 2025-06-13 | Date of issuer's registration statement on Form S-3 filing with the Securities and Exchange Commission. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Date of Schedule 13G filing. |
Keywords
Lexeo Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.